Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
Rezolute (RZLT) Stock Price & Analysis
240 Followers
RZLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $3.69
Previous Close$2.99
Volume228.28K
Average Volume (3M)349.79K
Market Cap
$119.98M
Enterprise Value$29.89M
Total Cash (Recent Filing)$92.60M
Total Debt (Recent Filing)$2.51M
Price to Earnings (P/E)-2.7
Beta-0.09
Next Earnings
May 14, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding39,625,271
10 Day Avg. Volume199,645
30 Day Avg. Volume349,786
Standard Deviation0.26
R-Squared0.00798
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.29
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$9.60Price Target Upside236.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Rezolute News
PremiumCompany Announcements
Rezolute to Present Phase 2 RIZE Study at PES Meeting
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsRZ358 shows promise in treating rare diseases with successful Phase 2b study results, potentially improving quality of life for children with congenital hyperinsulinism.
Financial StabilityRezolute's solid financial position, with significant cash reserves and no debt, ensures continued operation and research into groundbreaking treatments for rare diseases.
Regulatory MilestonesFavorable regulatory feedback and alignment with the FDA on advancing RZ358's clinical trials highlight the potential for expedited development and market introduction.
Bears Say
Competition And EfficacyDiazoxide, SST agonists and everolimus are 'not very effective' in treating tumor associated severe hypoglycemia.
Drug EfficacyKallikrein inhibitors have been disappointing in the clinic.
Regulatory HurdlesRZ358 faces a partial clinical hold in the US, introducing uncertainty in the timeline for US market access.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $0.72 and its highest was $3.69 in the past 12 months.
What is Rezolute’s market cap?
Currently, no data Available
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is May 14, 2024 which is today.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Feb 13, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.303 by $0.033.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -$0.3.
How many shares outstanding does Rezolute have?
Rezolute has 40,127,647 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.303. Following the earnings report the stock price went up 13.761%.
Which hedge fund is a major shareholder of Rezolute?
Among the largest hedge funds holding Rezolute’s share is Blackstone Inc.. It holds Rezolute’s shares valued at 2M.
---
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.60 (236.84% Upside)
$9.60 (236.84% Upside)
Insider Transactions
Bought Shares
Worth $17.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 18.5%
Last 30 Days ▲ 18.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.06%
12-Months-Change
Fundamentals
Return on Equity
-48.79%
Trailing 12-Months
Asset Growth
-31.99%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
---
RZLT Stock 12 Month Forecast
Average Price Target
$9.60
▲(236.84% Upside)
Technical Analysis
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+13.84%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +13.84% per trade.
---